The EHBP1 Knockout A2780 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population generated by targeted disruption of the EHBP1 gene in the A2780 human ovarian carcinoma cell line. This loss-of-function model comprises a heterogeneous pool of cells with diverse genetic alterations at the EHBP1 locus, minimizing clonal bias and reflecting population-level variability. The polyclonal format is advantageous for studies requiring a broad representation of knockout phenotypes without the selection pressure of monoclonal isolation.
The parental A2780 cell line is a well-characterized human ovarian endometrioid adenocarcinoma model, originally derived from an untreated patient and widely used in ovarian cancer research due to its epithelial morphology, rapid growth, and responsiveness to platinum-based chemotherapeutics like cisplatin. A2780 cells retain functional EGFR signaling, active clathrin-mediated endocytosis, and a dynamic actin cytoskeleton, providing a physiologically relevant background for interrogating endocytic adaptor proteins in tumor biology.
EHBP1 (EH domain-binding protein 1) functions as an endocytic adaptor that physically couples clathrin-mediated endocytosis to the actin cytoskeleton. It simultaneously interacts with EH domain-containing proteins, such as EPS15 and EPS15R, and with actin filaments, thereby coordinating actin polymerization at sites of clathrin-coated pit formation. Within the endocytic pathway, EHBP1 operates downstream of receptor activation and upstream of dynamin-mediated vesicle scission, facilitating the internalization of cargoes including EGFR. This adaptor is integrated into a molecular network that includes clathrin, the AP-2 complex, dynamin, and actin, all of which are critical for the spatiotemporal regulation of endocytic trafficking and signal modulation.
In A2780 ovarian carcinoma cells, disruption of EHBP1 is anticipated to impair the orchestrated internalization and intracellular trafficking of EGFR, potentially delaying receptor degradation and altering downstream MAPK and AKT signaling cascades. Because EGFR overexpression and dysregulated trafficking are common in ovarian malignancies, this knockout model serves as a powerful platform for dissecting how endocytic defects contribute to sustained oncogenic signaling and resistance to apoptosis. Additionally, as EHBP1 links endocytosis to actin cytoskeleton remodeling, its loss may disrupt cortical actin organization, affecting cell migration and invasive capacity??phenotypes directly relevant to ovarian cancer metastasis.
The EHBP1 Knockout A2780 Polyclonal Cells are suitable for diverse experimental applications, including transferrin uptake assays to measure clathrin-mediated endocytosis rates, Western blot analysis of EGFR and phosphorylated signaling intermediates, and immunofluorescence imaging to assess receptor localization and actin cytoskeleton architecture. Functional assays such as wound healing and Boyden chamber migration can quantify changes in cell motility, while cisplatin sensitivity assays explore the impact of EHBP1 loss on chemotherapeutic response. This polyclonal knockout model is also well-suited for high-throughput functional genomic screens, protein?Cprotein interaction studies, and live-cell imaging experiments focused on endocytic trafficking in ovarian cancer. For further information, please contact Ascent Research.
